京都府立医科大学 血液内科

業績

当教室関連研究の英文論文

2015年

Nakai N, Ohshita A, Kuroda J, Katoh N. Adult T-cell Lymphoma Complicated with Epidermodysplasia Verruciformis-like Eruptions. Acta Dermatovenerol Croat. 2015 Dec;23(4):304-7.(京都府立医科大皮膚科との共同研究)

Nagoshi H, Taki T, Chinen Y, Tatekawa S, Tsukamoto T, Maegawa S, Yamamoto-Sugitani M, Tsutsumi Y, Kobayashi T, Matsumoto Y, Horiike S, Okuno Y, Fujiwara S, Hata H, Kuroda J, Taniwaki M. Transcriptional dysregulation of the deleted in colorectal carcinoma gene in multiple myeloma and monoclonal gammopathy of undetermined significance. Genes Chromosomes Cancer. 2015 Dec;54(12):788-95.

Shimura Y, Horiike S, Tsutsumi Y, Hatsuse M, Okano A, Fuchida S, Kobayashi T, Matsumoto Y, Kuroda J, Kawata-Iida E, Uchiyama H, Uoshima N, Shimazaki C, Kaneko H, Kobayashi Y, Taniwaki M. The longitudinal analysis of large granular lymphocytosis in patients with Philadelphia chromosome-positive leukemia treated with dasatinib. Int J Hematol. 2015 Oct;102(4):426-33.(京都府立医科大学血液・腫瘍内科と関連施設の共同研究)

Mizutani S, Yoshida T, Zhao X, Nimer SD, Taniwaki M, Okuda T. Loss of RUNX1/AML1 arginine-methylation impairs peripheral T cell homeostasis. Br J Haematol. 2015 Sep;170(6):859-73.

Lonial S, Dimopoulos M, Palumbo A, White D, Grosicki S, Spicka I, Walter-Croneck A, Moreau P, Mateos MV, Magen H, Belch A, Reece D, Beksac M, Spencer A, Oakervee H, Orlowski RZ, Taniwaki M, Röllig C, Einsele H, Wu KL, Singhal A, San-Miguel J, Matsumoto M, Katz J, Bleickardt E, Poulart V, Anderson KC, Richardson P; ELOQUENT-2 Investigators. Elotuzumab Therapy for Relapsed or Refractory Multiple Myeloma. N Engl J Med. 2015 Aug 13;373(7):621-31.(多施設共同研究)

Yokokawa Y, Taki T, Chinen Y, Kobayashi S, Nagoshi H, Akiyama M, Morimoto A, Ida H, Taniwaki M. Unique clonal relationship between T-cell acute lymphoblastic leukemia and subsequent Langerhans cell histiocytosis with TCR rearrangement and NOTCH1 mutation. Genes Chromosomes Cancer. 2015 Jul;54(7):409-17.

Ogura M, Uchida T, Terui Y, Hayakawa F, Kobayashi Y, Taniwaki M, Takamatsu Y, Naoe T, Tobinai K, Munakata W, Yamauchi T, Kageyama A, Yuasa M, Motoyama M, Tsunoda T, Hatake K. Phase I study of OPB-51602, an oral inhibitor of signal transducer and activator of transcription 3, in patients with relapsed/refractory hematological malignancies. Cancer Sci. 2015 Jul;106(7):896-901.(多施設共同研究)

Kaneko H, Tsutsumi Y, Fujino T, Kuwahara S, Ohshiro M, Iwai T, Kuroda J, Yokota S, Horiike S, Taniwaki M. Favorable Event Free-Survival of High-Dose Chemotherapy Followed by Autologous Hematopoietic Stem Cell Transplantation for Higher Risk Diffuse Large B-Cell Lymphoma in First Complete Remission. Hematol Rep. 2015 Jun 8;7(2):5812.

Tatekawa S, Umemura K, Fukuyama R, Kohno A, Taniwaki M, Kuroda J, Morishita Y. Thalidomide for tocilizumab-resistant ascites with TAFRO syndrome. Clin Case Rep. 2015 Jun;3(6):472-8.

Kuroda J, Kobayashi T, Taniwaki M. Prognostic indicators of lenalidomide for multiple myeloma: consensus and controversy. Expert Rev Anticancer Ther. 2015;15(7):787-804.

Suzuki K, Ogura M, Abe Y, Suzuki T, Tobinai K, Ando K, Taniwaki M, Maruyama D, Kojima M, Kuroda J, Achira M, Iizuka K. Phase 1 study in Japan of siltuximab, an anti-IL-6 monoclonal antibody, in relapsed/refractory multiple myeloma. Int J Hematol. 2015 Mar;101(3):286-94. (多施設共同研究)

Nakaseko C, Takahashi N, Ishizawa K, Kobayashi Y, Ohashi K, Nakagawa Y, Yamamoto K, Miyamura K, Taniwaki M, Okada M, Kawaguchi T, Shibata A, Fujii Y, Ono C, Ohnishi K. A phase 1/2 study of bosutinib in Japanese adults with Philadelphia chromosome-positive chronic myeloid leukemia. Int J Hematol. 2015 Feb;101(2):154-64. (多施設共同研究)

Kanemaru M, Tashima S, Yamazaki A, Masuda K, Nagoshi H, Kobayashi T, Kuroda J, Hiruma M, Taniwaki M, Katoh N. Disseminated mucormycosis due to Rhizopus oryzae diagnosed by skin biopsy. J Dermatol. 2015 Jan;42(1):100-1. (京都府立医科大学皮膚科との共同研究)

Kobayashi T, Kuroda J, Fuchida S, Kaneko H, Yagi H, Shibayama H, Tanaka H, Kosugi S, Uoshima N, Kobayashi M, Adachi Y, Ohta K, Ishii K, Uchiyama H, Matsuda, M, Nakatani E, Tsudo M, Shimazaki C, Takaori-Kondo A, Nomura S, Matsumura I, Taniwaki M, Kanakura Y; KMF investigators. Impact of early use of lenalidomide and low-dose dexamethasone on clinical outcomes in patients with relapsed/refractory multiple myeloma. Int J Hematol. 2015 Jan;101(1):37-45. (KMF共同研究)

2014年

Kaneko H, Shimura K, Yoshida M, Ohkawara Y, Ohshiro M, Tsutsumi Y, Iwai T, Horiike S, Yokota S, Taniwaki M. Acute lymphoblastic leukemia with eosinophilia lacking peripheral blood leukemic cell: a rare entity. Indian J Hematol Blood Transfus. 2014 Sep;30(Suppl 1):80-3.

Chinen Y, Kuroda J, Shimura Y, Nagoshi H, Kiyota M, Yamamoto-Sugitani M, Mizutani S, Sakamoto N, Ri M, Kawata E, Kobayashi T, Matsumoto Y, Horiike S, Iida S, Taniwaki M. Phosphoinositide protein kinase PDPK1 is a crucial cell signaling mediator in multiple myeloma. Cancer Res. 2014 Dec 15;74(24):7418-29.

Chinen Y, Sakamoto N, Nagoshi H, Taki T, Maegawa S, Tatekawa S, Tsukamoto T, Mizutani S, Shimura Y, Yamamoto-Sugitani M, Kobayashi T, Matsumoto Y, Horiike S, Kuroda J, Taniwaki M. 8q24 amplified segments involve novel fusion genes between NSMCE2 and long noncoding RNAs in acute myelogenous leukemia. J Hematol Oncol. 2014 Sep 23;7:68.

Kuroda J, Mizutani S, Shimura Y, Maegawa S, Nagoshi H, Chinen Y, Tatekawa S, Tsukamoto T, Mizuno Y, Yamamoto-Sugitani M, Kobayashi T, Matsumoto Y, Horiike S, Taniwaki M. Intravenous bortezomib for multiple myeloma that has progressed after subcutaneous bortezomib therapy. Ann Hematol. 2015 Apr;94(4):687-9.

Kaneko H, Shimura K, Kuwahara S, Ohshiro M, Tsutsumi Y, Iwai T, Horiike S, Yokota S, Ohkawara Y, Taniwaki M. Inversion of chromosome 7q22 and q36 as a sole abnormality presenting in myelodysplastic syndrome: a case report. J Med Case Rep. 2014 Aug 5;8:268.

Nagai K, Nakahata S, Shimosaki S, Tamura T, Kondo Y, Baba T, Taki T, Taniwaki M, Kurosawa G, Sudo Y, Okada S, Sakoda S, Morishita K. Development of a complete human anti-human transferrin receptor C antibody as a novel marker of oral dysplasia and oral cancer. Cancer Med. 2014 Aug;3(4):1085-99.

Maegawa S, Kuroda J, Kobayashi T, Fuchida S, Kawata E, Kamitsuji Y, Tsutsumi Y, Iwai T, Nakao M, Kaneko H, Uoshima N, Shimazaki C, Kobayashi Y, Horiike S, Yamamoto A, Kawahito Y, Taniwaki M. Clinical manifestation and prognostic factors of 32 Japanese patients with autoimmune disease-associated diffuse large B-cell lymphoma. Leuk Lymphoma. 2015 Mar;56(3):785-8.

Sato Y, Kondo M, Inagaki A, Komatsu H, Okada C, Naruse K, Sahashi T, Kuroda J, Ogura H, Uegaki S, Yoshida T, Mori Y, Sawada H, Watanabe S, Sugiura H, Endo Y, Yoshimoto N, Toyama T, Iida S, Yamada K, Kimura K, Wakita A. Highly frequent and enhanced injection site reaction induced by peripheral venous injection of fosaprepitant in anthracycline-treated patients. J Cancer. 2014 Apr 24;5(5):390-7. (多施設共同研究)

Shimura Y, Kuroda J, Sasaki N, Uchiyama H, Ohshiro M, Matsumura Y, Nagoshi H, Mizutani S, Yamamoto-Sugitani M, Kobayashi T, Matsumoto Y, Horiike S, Taniwaki M. Reduced-intensity allogeneic stem cell transplantation for co-emergence of chemotherapy-refractory follicular lymphoma and therapy-related myelodysplastic syndrome. Case Rep Oncol. 2014 Mar 13;7(1):188-94.

Matsumoto Y, Horiike S, Maegawa S, Isohisa T, Sakamoto N, Chinen Y, Nakayama R, Kiyota M, Nagoshi H, Mizutani S, Shimura Y, Sugitani M, Kobayashi T, Nakai N, Kuroda J, Taniwaki M. A case of rheumatoid arthritis/methotrexate-associated primary cutaneous diffuse large B-cell lymphoma, leg type. Intern Med. 2014;53(11):1177-81.

Kuroda J, Shimura Y, Mizutani S, Nagoshi H, Kiyota M, Chinen Y, Maegawa S, Kobayashi T, Matsumoto Y, Horiike S, Taniwaki M. Azacitidine-associated acute interstitial pneumonitis. Intern Med. 2014;53(11):1165-9.

Kuroda J, Kodama A, Chinen Y, Shimura Y, Mizutani S, Nagoshi H, Kobayashi T, Matsumoto Y, Nakaya Y, Tamura A, Kobayashi Y, Naito H, Taniwaki M. NS-018, a selective JAK2 inhibitor, preferentially inhibits CFU-GM colony formation by bone marrow mononuclear cells from high-risk myelodysplastic syndrome patients. Leuk Res. 2014 May;38(5):619-24.

Kuroda J, Shimura Y, Ohta K, Tanaka H, Shibayama H, Kosugi S, Fuchida S, Kobayashi M, Kaneko H, Uoshima N, Ishii K, Nomura S, Taniwaki M, Takaori-Kondo A, Shimazaki C, Tsudo M, Hino M, Matsumura I, Kanakura Y; Kansai Myeloma Forum Investigators. Limited value of the international staging system for predicting long-term outcome of transplant-ineligible, newly diagnosed, symptomatic multiple myeloma in the era of novel agents. Int J Hematol. 2014 Apr;99(4):441-9.

Ogura M, Ishida T, Hatake K, Taniwaki M, Ando K, Tobinai K, Fujimoto K, Yamamoto K, Miyamoto T, Uike N, Tanimoto M, Tsukasaki K, Ishizawa K, Suzumiya J, Inagaki H, Tamura K, Akinaga S, Tomonaga M, Ueda R. Multicenter Phase II Study of Mogamulizumab (KW-0761), a Defucosylated Anti-CC Chemokine Receptor 4 Antibody, in Patients With Relapsed Peripheral T-Cell Lymphoma and Cutaneous T-Cell Lymphoma. J Clin Oncol. 2014 Apr 10;32(11):1157-63. (多施設共同研究)

Nakahata S, Ichikawa T, Maneesaay P, Saito Y, Nagai K, Tamura T, Manachai N, Yamakawa N, Hamasaki M, Kitabayashi I, Arai Y, Kanai Y, Taki T, Abe T, Kiyonari H, Shimoda K, Ohshima K, Horii A, Shima H, Taniwaki M, Yamaguchi R, Morishita K. Loss of NDRG2 expression activates PI3K-AKT signalling via PTEN phosphorylation in ATLL and other cancers. Nat Commun. 2014 Feb 26;5:3393. (多施設共同研究)

Chonabayashi K, Tamori S, Taniwaki M, Fujita H, Shimazu Y, Matsui Y, Hishizawa M, Usami K, Takaori-Kondo A. Refractory IGκ/IRF4-positive DLBCL with CDKN2A/2B deletion. Ann Hematol. 2014 May;93(5):893-4. (泰玄会病院、京都大学との共同研究)

Kobayashi S, Taki T, Nagoshi H, Chinen Y, Yokokawa Y, Kanegane H, Matsumoto Y, Kuroda J, Horiike S, Nishida K, Taniwaki M. Identification of novel fusion genes with 28S ribosomal DNA in hematologic malignancies. Int J Oncol. 2014 Apr;44(4):1193-8.

Chinen Y, Taki T, Tsutsumi Y, Kobayashi S, Matsumoto Y, Sakamoto N, Kuroda J, Horiike S, Nishida K, Ohno H, Uike N, Taniwaki M. The leucine twenty homeobox (LEUTX) gene, which lacks a histone acetyltransferase domain, is fused to KAT6A in therapy-related acute myeloid leukemia with t(8;19)(p11;q13). Genes Chromosomes Cancer. 2014 Apr;53(4):299-308.

Iriyama N, Asou N, Miyazaki Y, Yamaguchi S, Sato S, Sakura T, Maeda T, Handa H, Takahashi M, Ohtake S, Hatta Y, Sakamaki H, Honda S, Taki T, Taniwaki M, Miyawaki S, Ohnishi K, Kobayashi Y, Naoe T. Normal karyotype acute myeloid leukemia with the CD7+ CD15+ CD34+ HLA-DR + immunophenotype is a clinically distinct entity with a favorable outcome. Ann Hematol. 2014 Jan 19. [Epub ahead of print]

Fujisawa S, Nakamae H, Ogura M, Ishizawa K, Taniwaki M, Utsunomiya A, Matsue K, Takamatsu Y, Usuki K, Tanimoto M, Ishida Y, Akiyama H, Onishi S. Efficacy and safety of dasatinib versus imatinib in Japanese patients with newly diagnosed chronic-phase chronic myeloid leukemia (CML-CP): Subset analysis of the DASISION trial with 2-year follow-up. Int J Hematol. 2014 Feb;99(2):141-53. (多施設共同研究)

Nakayama R, Kuroda J, Taniyama N, Yamamoto-Sugitani M, Wada S, Kiyota M, Mizutani S, Chinen Y, Matsumoto Y, Nagoshi H, Shimura Y, Kobayashi T, Horiike S, Sato K, Taniwaki M. Suppression of SERPINA1-albumin complex formation by galectin-3 overexpression leads to paracrine growth promotion of chronic myelogenous leukemia cells. Leuk Res. 2014 Jan;38(1):103-8.

2013年

Yoshida N, Hosokawa T, Ishikawa T, Yagi N, Kokura S, Naito Y, Nakanishi M, Kokuba Y, Otsuji E, Kuroboshi H, Taniwaki M, Taguchi T, Hosoi H, Nakamura T, Miki T. Efficacy of goshajinkigan for oxaliplatin-induced peripheral neuropathy in colorectal cancer patients. J Oncol. 2013 Epub 2013 Nov 7.

Kuroda J, Nagoshi H, Shimura Y, Taniwaki M. Elotuzumab and daratumumab: emerging new monoclonal antibodies for multiple myeloma. Expert Rev Anticancer Ther. 2013 Sep;13(9):1081-8.

Nagoshi H, Kuroda J, Kobayashi T, Maegawa S, Chinen Y, Kiyota M, Nakayama R, Mizutani S, Shimura Y, Yamamoto-Sugitani M, Matsumoto Y, Horiike S, Taniwaki M. Clinical manifestation of angioimmunoblastic T-cell lymphoma with exuberant plasmacytosis. Int J Hematol. 2013 Sep;98(3):366-74.

Kiyota M, Kuroda J, Yamamoto-Sugitani M, Shimura Y, Nakayama R, Nagoshi H, Mizutani S, Chinen Y, Sasaki N, Sakamoto N, Kobayashi T, Matsumoto Y, Horiike S, Taniwaki M. FTY720 induces apoptosis of chronic myelogenous leukemia cells via dual activation of BIM and BID and overcomes various types of resistance to tyrosine kinase inhibitors. Apoptosis. 2013 Nov;18(11):1437-46.

Nakayama R, Matsumoto Y, Horiike S, Kobayashi S, Nakao R, Nagoshi H, Tsutsumi Y, Nishimura A, Shimura K, Kobayashi T, Uchiyama H, Kuroda J, Taki T, Inaba T, Nishida K, Yokota S, Yanagisawa A, Taniwaki M. Close pathogenetic relationship between ocular immunoglobulin G4-related disease (IgG4-RD) and ocular adnexal mucosa-associated lymphoid tissue (MALT) lymphoma. Leuk Lymphoma. 2013 Aug 13. [Epub ahead of print]

Iriyama N, Hatta Y, Takeuchi J, Ogawa Y, Ohtake S, Sakura T, Mitani K, Ishida F, Takahashi M, Maeda T, Izumi T, Sakamaki H, Miyawaki S, Honda S, Miyazaki Y, Taki T, Taniwaki M, Naoe T. CD56 expression is an independent prognostic factor for relapse in acute myeloid leukemia with t(8;21). Leuk Res. 2013 Sep;37(9):1021-6. (多施設共同研究)

Tsutsumi Y, Chinen Y, Sakamoto N, Nagoshi H, Nishida K, Kobayashi S, Yokokawa Y, Taki T, Sasaki N, Yamamoto-Sugitani M, Kobayashi T, Matsumoto Y, Horiike S, Kuroda J, Taniwaki M. Deletion or methylation of CDKN2A/2B and PVT1 rearrangement occur frequently in highly aggressive B-cell lymphomas harboring 8q24 abnormality. Leuk Lymphoma, 2013 Dec;54(12):2760-4.

Shimura Y, Kuroda J, Uchiyama H, Kawata-Iida E, Tsutsumi Y, Nagoshi H, Mizutani S, Yamamoto-Sugitani M, Matsumoto Y, Kobayashi T, Horiike S, Shimazaki C, Kaneko H, Kobayashi Y, Taniwaki M. Hematopoietic progenitor cell mobilization using low-dose cyclophosphamide and granulocyte colony-stimulating factor for multiple myeloma. J Clin Apher. 2013 Jun 27. (京都府立医科大学血液・腫瘍内科と関連施設の共同研究)

Chinen Y, Kuroda J, Ohshiro M, Shimura Y, Mizutani S, Nagoshi H, Sasaki N, Nakayama R, Kiyota M, Yamamoto-Sugitani M, Kobayashi T, Matsumoto Y, Horiike S, Taniwaki M. Low ADAMTS-13 activity during hemorrhagic events with disseminated intravascular coagulation. Int J Hematol. 2013 Apr;97(4):511-9.

Yanada M, Tsuzuki M, Fujita H, Fujimaki K, Fujisawa S, Sunami K, Taniwaki M, Ohwada A, Tsuboi K, Maeda A, Takeshita A, Ohtake S, Miyazaki Y, Atsuta Y, Kobayashi Y, Naoe T, Emi N. Phase 2 study of arsenic trioxide followed by autologous hematopoietic cell transplantation for relapsed acute promyelocytic leukemia. Blood. 2013 Apr 18;121(16):3095-102.(多施設共同研究)

Endo M, Yasui K, Zen Y, Gen Y, Zen K, Tsuji K, Dohi O, Mitsuyoshi H, Tanaka S, Taniwaki M, Nakanuma Y, Arii S, Yoshikawa T. Alterations of the SWI/SNF chromatin remodelling subunit-BRG1 and BRM in hepatocellular carcinoma. Liver Int. 2013 Jan;33(1):105-17.(消化器内科との共同研究)

Kuroda J, Shimura Y, Yamamoto-Sugitani M, Sasaki N, Taniwaki M. Multifaceted mechanisms for cell survival and drug targeting in chronic myelogenous leukemia. Curr Cancer Drug Targets. 2013 Jan;13(1):69-79.

Komori S, Asai J, Takenaka H, Kuroda J, Hirai Y, Iwatsuki K, Katoh N. Chronic active Epstein-Barr virus infection with progression to large granular lymphocytic leukemia. J Dermatol, in print

Kobayashi T, Kuroda J, Fuchida S, Murakami S, Hatsuse M, Okano A, Iwai T, Tsutsumi Y, Kamitsuji Y, Akaogi T, Kawata-Iida E, Shimizu D, Uchiyama H, Matsumoto Y, Horiike S, Nakao M, Takahashi R, Kaneko H, Uoshima N, Kobayashi Y, Shimazaki C, Taniwaki M. The response to second-line induction with bortezomib and dexamethasone predictive of long-term outcome prior to high-dose chemotherapy with autologous stem cell transplantation for multiple myeloma. Intern Med, 2013;52(9):961-8. (京都府立医科大学血液・腫瘍内科と関連施設の共同研究)

2012年

Matsumura Y, Kuroda J, Shimura Y, Kiyota M, Yamamoto-Sugitani M, Kobayashi T, Matsumoto Y, Horiike S, Taniwaki M. Cyclosporine A and reduced-intensity conditioning allogeneic stem cell transplantation for relapsed angioimmunoblastic T cell lymphoma with hemophagocytic syndrome. Intern Med. 2012;51(19):2785-7.

Shimura Y, Kuroda J, Ri M, Nagoshi H, Yamamoto-Sugitani M, Kobayashi T, Kiyota M, Nakayama R, Mizutani S, Chinen Y, Sakamoto N, Matsumoto Y, Horiike S, Shiotsu Y, Iida S, Taniwaki M. RSK2(Ser227) at N-terminal kinase domain is a potential therapeutic target for multiple myeloma. Mol Cancer Ther. 2012 Dec;11(12):2600-9.

Kobayashi T, Tsutsumi Y, Sakamoto N, Nagoshi H, Yamamoto-Sugitani M, Shimura Y, Mizutani S, Matsumoto Y, Nishida K, Horiike S, Asano N, Nakamura S, Kuroda J, Taniwaki M. Double-hit lymphomas constitute a highly aggressive subgroup in diffuse large B-cell lymphomas in the era of rituximab. Jpn J Clin Oncol. 2012 Nov;42(11):1035-42.

Liu F, Asano N, Tatematsu A, Oyama T, Kitamura K, Suzuki K, Yamamoto K, Sakamoto N, Taniwaki M, Kinoshita T, Nakamura S. Plasmablastic lymphoma of the elderly: a clinicopathological comparison with age-related Epstein-Barr virus-associated B cell lymphoproliferative disorder. Histopathology. 2012 Dec;61(6):1183-97.(多施設共同研究)

Nagoshi H, Taki T, Hanamura I, Nitta M, Otsuki T, Nishida K, Okuda K, Sakamoto N, Kobayashi S, Yamamoto-Sugitani M, Tsutsumi Y, Kobayashi T, Matsumoto Y, Horiike S, Kuroda J, Taniwaki M. Frequent PVT1 rearrangement and novel chimeric genes PVT1-NBEA and PVT1-WWOX occur in multiple myeloma with 8q24 abnormality. Cancer Res. 2012 Oct 1;72(19):4954-62.

Yao H, Ashihara E, Strovel JW, Nakagawa Y, Kuroda J, Nagao R, Tanaka R, Yokota A, Takeuchi M, Hayashi Y, Shimazaki C, Taniwaki M, Strand K, Padia J, Hirai H, Kimura S, Maekawa T. AV-65, a novel Wnt/β-catenin signal inhibitor, successfully suppresses progression of multiple myeloma in a mouse model. Blood Cancer J. 2011 Nov;1(11):e43.(京都大学輸血細胞治療部との共同研究)

Yamamoto-Sugitani M, Kuroda J, Shimura Y, Nagoshi H, Chinen Y, Ohshiro M, Mizutani S, Kiyota M, Nakayama R, Kobayashi T, Uchiyama H, Matsumoto Y, Horiike S, Taniwaki M. Comprehensive cytogenetic study of primary cutaneous gamma-delta T-cell lymphoma by means of spectral karyotyping and genome-wide single nucleotide polymorphism array. Cancer Genet. 2012 Sep;205(9):459-64.

Kiyota M, Kobayashi T, Fuchida S, Yamamoto-Sugitani M, Ohshiro M, Shimura Y, Mizutani S, Nagoshi H, Sasaki N, Nakayama R, Chinen Y, Sakamoto N, Uchiyama H, Matsumoto Y, Horiike S, Shimazaki C, Kuroda J, Taniwaki M. Monosomy 13 in metaphase spreads is a predictor of poor long-term outcome after bortezomib plus dexamethasone treatment for relapsed/refractory multiple myeloma. Int J Hematol. 2012 May;95(5):516-26.

Kondo Y, Nagai K, Nakahata S, Saito Y, Ichikawa T, Suekane A, Taki T, Iwakawa R, Enari M, Taniwaki M, Yokota J, Sakoda S, Morishita K. Overexpression of the DNA sensor proteins, absent in melanoma 2 and interferon-inducible 16, contributes to tumorigenesis of oral squamous cell carcinoma with p53 inactivation. Cancer Sci. 2012 Apr;103(4):782-90. (宮崎大学との共同研究)

Tokunaga T, Shimada K, Yamamoto K, Chihara D, Ichihashi T, Oshima R, Tanimoto M, Iwasaki T, Isoda A, Sakai A, Kobayashi H, Kitamura K, Matsue K, Taniwaki M, Tamashima S, Saburi Y, Masunari T, Naoe T, Nakamura S, Kinoshita T. Retrospective analysis of prognostic factors for angioimmunoblastic T-cell lymphoma: a multicenter cooperative study in Japan. Blood. 2012 Mar 22;119(12):2837-43. (多施設共同研究)

Matsuda A, Taniwaki M, Jinnai I, Harada H, Watanabe M, Suzuki K, Yanagita S, Suzuki T, Yoshida Y, Kimura A, Tsudo M, Tohyama K, Takatoku M, Ozawa K. Morphologic analysis in myelodysplastic syndromes with del(5q) treated with lenalidomide. A Japanese multiinstitutional study. Leuk Res. 2012;36(5):575-80. (多施設共同研究)

Chinen Y, Nakao M, Sugitani-Yamamoto M, Kiyota M, Horiike S, Kuroda J, Taniwaki M. Intravascular B-cell lymphoma with hypercalcemia as the initial presentation. Int J Hematol. 2011 Dec;94(6):567-70.

Ohshiro M, Kuroda J, Kobayashi Y, Akaogi T, Kawata E, Uoshima N, Kamitsuji Y, Kaneko H, Shimura K, Shimazaki C, Murakami S, Hatsuse M, Okano A, Kobayashi T, Uchiyama H, Matsumoto Y, Horiike S, Taniwaki M. ADAMTS-13 activity can predict the outcome of disseminated intravascular coagulation in hematologic malignancies treated with recombinant human soluble thrombomodulin. Am J Hematol. 2012;87(1):116-9. (京都府立医科大学血液・腫瘍内科と関連施設の共同研究)

Kobayashi T, Kuroda J, Uchiyama H, Matsumoto Y, Horiike S, Taniwaki M. Successful treatment of chemotherapy-refractory angioimmunoblastic T cell lymphoma with cyclosporin A. Acta Haematol. 2012;127(1):10-5.

Gotou M, Hanamura I, Nagoshi H, Wakabayashi M, Sakamoto N, Tsunekawa N, Horio T, Goto M, Mizuno S, Takahashi M, Suganuma K, Yamamoto H, Hiramatsu A, Watarai M, Shikami M, Imamura A, Mihara H, Taki T, Miwa H, Taniwaki M, Nitta M. Establishment of a novel human myeloid leukemia cell line, AMU-AML1, carrying t(12;22)(p13;q11) without chimeric MN1-TEL and with high expression of MN1. Genes Chromosomes Cancer. 2012 Jan;51(1):42-53. (愛知医大との共同研究)

2011年

Kaneko H, Shimura K, Horiike S, Kuroda J, Matsumoto Y, Yokota S, Nishida K, Ohkawara Y, Taniwaki M. Cytogenetic analysis of de novo CD5-positive diffuse large B-cell lymphoma. Asia Pac J Clin Oncol, 7:346-350, 2011

Kobayashi T, Kuroda J, Kiyota M, Nakayama R, Taniwaki M. Clinical studies of molecular targeted therapy for multiple myeloma. Translational Medicine, 2011 S:2-002 (http://www.omicsonline.org/2161-1025/2161-1025-S2-002.pdf)

Chinen Y, Nakao M, Sugitani-Yamamoto M, Kiyota M, Horiike S, Kuroda J, Taniwaki M. Intravascular B-cell lymphoma with hypercalcemia as the initial presentation. Int J Hematol, 94:567-570, 2011

Yamamoto-Sugitani M, Kuroda J, Ashihara E, Nagoshi H, Kobayashi T, Matsumoto Y, Sasaki N, Shimura Y, Kiyota M, Nakayama R, Akaji K, Taki T, Uoshima N, Kobayashi Y, Horiike S, Maekawa T, Taniwaki M. Galectin-3 induced by leukemia microenvironment promotes drug resistance and bone marrow lodgment in chronic myelogenous leukemia. Proc Natl Acad Sci USA, 108:17468-17473, 2011

Watanabe T, Tobinai K, Shibata T, Tsukasaki K, Morishima Y, Maseki N, Kinoshita T, Suzuki T, Yamaguchi M, Ando K, Ogura M, Taniwaki M, Uike N, Takeuchi K, Nawano S, Terauchi T, Hotta T. Phase II/III study of R-CHOP-21 versus R-CHOP-14 for untreated indolent B-cell non-Hodgkin's lymphoma: JCOG 0203 trial. J Clin Oncol. 29(30):3990-3998, 2011. (多施設共同研究)

Yao H, Ashihara E, Strovel JW, Nakagawa Y, Kuroda J, Nagao R, Tanaka R, Yokota A, Takeuchi M, Hayashi Y, Shimazaki C, Taniwaki M, Strand K, Padia J, Hirai H, Kimura S, Maekawa T. AV-65, a novel Wnt/β-catenin signal inhibitor, successfully suppresses progression of multiple myeloma in a mouse model. Blood Cancer J, in press (京都大学輸血細胞治療部との共同研究)

Enomoto Y, Kitaura J, Hatakeyama K, Watanuki J, Akasaka T, Kato N, Shimanuki M, Nishimura K, Takahashi M, Taniwaki M, Haferlach C, Siebert R, Dyer MJ, Asou N, Aburatani H, Nakakuma H, Kitamura T, Sonoki T.  Eμ/miR-125b transgenic mice develop lethal B-cell malignancies. Leukemia. 25(12):1849-56, 2011 (東京大学医科学研究所との共同研究)

Ogura M, Ando K, Taniwaki M, Watanabe T, Uchida T, Ohmachi K, Matsumoto Y, Tobinai K; for the Japanese Bendamustine Lymphoma Study Group.  Feasibility and pharmacokinetic study of bendamustine hydrochloride in combination with rituximab in relapsed or refractory aggressive B cell non-Hodgkin's lymphoma(6).  Cancer Sci. 102(9):1687-92, 2011. (多施設共同研究)

Uchida T, Ogawa Y, Kobayashi Y, Ishikawa T, Ohashi H, Hata T, Usui N, Taniwaki M, Ohnishi K, Akiyama H, Ozawa K, Ohyashiki K, Okamoto S, Tomita A, Nakao S, Tobinai K, Ogura M, Ando K, Hotta T. Phase I and II study of azacitidine in Japanese patients with myelodysplastic syndromes. Cancer Sci. 102(9):1680-1686, 2011(多施設共同研究)

Kobayashi Y, Sakamaki H, Fujisawa S, Ando K, Yamamoto K, Okada M, Ishizawa K, Nagai T, Miyawaki S, Motoji T, Usui N, Iida S, Taniwaki M, Uoshima N, Seriu T, Ohno R. Lack of non-hematological cross intolerance of dasatinib to imatinib in imatinib-intolerant patients with Philadelphia chromosome positive chronic myeloid leukemia or acute lymphatic leukemia: a retrospective safety analysis. Int J Hematol. 2011;93(6):745-9. (多施設共同研究)

Kuroda J, Taniwaki M. Principles and current topics concerning management of tyrosine kinase inhibitor therapy for chronic myelogenous leukemia. Translational Medicine, 2011, S:2-001 (http://www.omicsonline.org/2161-1025/2161-1025-S2-001.pdf)

Kobayashi T, Kuroda J, Tsutsumi Y, Yamashita M, Yamamoto M, Ohshiro M, Nagoshi H, Sasaki N, Mizutani S, Shimura Y, Kiyota M, Nakayama R, Uchiyama H, Matsumoto Y, Horiike S, Taniwaki M. Successful treatment of chemotherapy-refractory angioimmunoblastic T-cell lymphoma with cyclosporin A. Acta Haematologica, 126:8-12, 2011

Nagoshi H, Horiike S, Kuroda J, Taniwaki M. Cytogenetic and Molecular Abnormalities in Myelodysplastic Syndrome. Curr Mol Med, 11:678-685, 2011

Sasaki N, Kuroda J, Nagoshi H, Yamamoto M, Kobayashi S, Tsutsumi Y, Kobayashi T, Shimura Y, Matsumoto Y, Taki T, Nishida K, Horiike S, Akao Y, Taniwaki M. Bcl-2 is a better therapeutic target than c-Myc, but attacking both could be a more effective treatment strategy for B cell lymphoma with concurrent Bcl-2 and c-Myc overexpression. Exp Hematol, 39:817-828, 2011(岐阜大学創薬医療情報研究科との共同研究)

Kaneko H, Shimura K, Fujii H, Sonoda Y, Nishida K, Matsumoto Y, Kuroda J, Horiike S, Yokota S, Taniwaki M, Ohkawara Y. Feasiability of modified MECP regimen as second-line chemotherapy for refractory or relapsed aggressive non-Hodgkin lymphoma. J Kyoto Pref Univ Med, 120:301-310, 2011

Mizutani S, Kuroda J, Shimura Y, Kobayashi T, Tsutsumi Y, Yamashita M, Yamamoto M, Ohshiro M, Sasaki N, Kiyota M, Nakayama R, Uchiyama H, Matsumoto Y, Horiike S, Nakamura S, Taniwaki M. Cyclosporine A for chemotherapy-resistant subcutaneous panniculitis-like T cell lymphoma with hemophagocytic syndrome. Acta Haematologica, 126:8-12, 2011

Kobayashi S, Taki T, Chinen Y, Tsutsumi Y, Ohshiro M, Kobayashi T, Matsumoto Y, Kuroda J, Horiike S, Nishida K, Taniwaki M. Identification of IGHC–BACH2 fusion transcripts resulting from cryptic chromosomal rearrangements of 14q32 with 6q15 in aggressive B-cell lymphoma/leukemia. Gene Chromosome Canc, 50, 207-216, 2011

Jin L, Tabe Y, Kimura S, Zhou Y, Kuroda J, Asou H, Inaba T, Konopleva M, Andreeff M, Miida T. Antiproliferative and proapoptotic activity of GUT-70 mediated through potent inhibition of Hsp90 in mantle cell lymphoma. Br J Cancer, 104, 91-100, 2011 (順天堂大学医学部臨床病理学教室との共同研究)

Htwe SS, Maeda M, Matsumoto R, Sakamoto N, Murakami S, Yamamoto S, Katoh M, Kumagai N, Hayashi H, Nishimura Y, Ohkura M, Wada H, Taniwaki M, Sugihara T, Otsuki T. Quick detection of overexpressed genes caused by myeloma-specific chromosomal translocations using multiplex RT-PCR. Int J Mol Med. 2011 Jun;27(6):789-94. (川崎医科大学 衛生学教室との共同研究)

Miyawaki S, Ohtake S, Fujisawa S, Kiyoi H, Shinagawa K, Usui N, Sakura T, Miyamura K, Nakaseko C, Miyazaki Y, Fujieda A, Nagai T, Yamane T, Taniwaki M, Takahashi M, Yagasaki F, Kimura Y, Asou N, Sakamaki H, Handa H, Honda S, Ohnishi K, Naoe T, Ohno R. A randomized comparison of 4 courses of standard-dose multiagent chemotherapy versus 3 courses of high-dose cytarabine alone in postremission therapy for acute myeloid leukemia in adults: the JALSG AML201 Study. Blood. 2011 Feb 24;117(8):2366-72. (多施設共同研究)

Ohtake S, Miyawaki S, Fujita H, Kiyoi H, Shinagawa K, Usui N, Okumura H, Miyamura K, Nakaseko C, Miyazaki Y, Fujieda A, Nagai T, Yamane T, Taniwaki M, Takahashi M, Yagasaki F, Kimura Y, Asou N, Sakamaki H, Handa H, Honda S, Ohnishi K, Naoe T, Ohno R. Randomized study of induction therapy comparing standard-dose idarubicin with high-dose daunorubicin in adult patients with previously untreated acute myeloid leukemia: the JALSG AML201 Study. Blood. 2011 Feb 24;117(8):2358-65. (多施設共同研究)

Isome K, Matsubara K, Taki T, Nigami H, Yura K, Iwata A, Wada T, Taniwaki M, Fukaya T. Spinal cord compression by epidural involvement over 21 vertebral levels in acute lymphoblastic leukemia. J Pediatr Hematol Oncol. 2011 Mar;33(2):153-7.

Asano N, Kinoshita T, Tamaru J, Ohshima K, Yoshino T, Niitsu N, Tsukamoto N, Hirabayashi K, Izutsu K, Taniwaki M, Morishima Y, Nakamura S. Cytotoxic molecule-positive classical Hodgkin's lymphoma: a clinicopathological comparison with cytotoxic molecule-positive peripheral T-cell lymphoma of not otherwise specified type. Haematologica. 2011;96(11):1636-1643. (多施設共同研究)

Kaneko H, Shimura K, Nishida K, Fujiwara Y, Matsumoto Y, Kuroda J, Horiike S, Yokota S, Ohkawara Y, Taniwaki M. Pure red cell aplasia caused by parvovirus B19 in two patients without chronic hemolysis. J Infect Chemother. 2011 Apr;17(2):268-71.